- Home
- MKZR vs IMNN Comparison
MKZR vs IMNN Comparison
Compare MKZR & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- IMNN
- Stock Information
- Founded
- MKZR 2012
- IMNN 1982
- Country
- MKZR United States
- IMNN United States
- Employees
- MKZR N/A
- IMNN N/A
- Industry
- MKZR
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- IMNN Health Care
- Exchange
- MKZR Nasdaq
- IMNN Nasdaq
- Market Cap
- MKZR 10.3M
- IMNN 12.1M
- IPO Year
- MKZR N/A
- IMNN 1985
- Fundamental
- Price
- MKZR $5.78
- IMNN $5.76
- Analyst Decision
- MKZR
- IMNN Buy
- Analyst Count
- MKZR 0
- IMNN 2
- Target Price
- MKZR N/A
- IMNN $182.61
- AVG Volume (30 Days)
- MKZR 69.1K
- IMNN 59.7K
- Earning Date
- MKZR 09-19-2025
- IMNN 11-06-2025
- Dividend Yield
- MKZR 38.99%
- IMNN N/A
- EPS Growth
- MKZR N/A
- IMNN N/A
- EPS
- MKZR N/A
- IMNN N/A
- Revenue
- MKZR $23,037,348.00
- IMNN N/A
- Revenue This Year
- MKZR N/A
- IMNN N/A
- Revenue Next Year
- MKZR N/A
- IMNN N/A
- P/E Ratio
- MKZR N/A
- IMNN N/A
- Revenue Growth
- MKZR 52.64
- IMNN N/A
- 52 Week Low
- MKZR $3.89
- IMNN $4.83
- 52 Week High
- MKZR $55.00
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- MKZR 50.44
- IMNN 34.44
- Support Level
- MKZR $4.76
- IMNN $5.50
- Resistance Level
- MKZR $6.40
- IMNN $6.96
- Average True Range (ATR)
- MKZR 0.42
- IMNN 0.34
- MACD
- MKZR 0.12
- IMNN 0.05
- Stochastic Oscillator
- MKZR 62.01
- IMNN 17.47
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).